CNS Lymphoma
Oncology
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
1 drug in development·1 company·2 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| epcoritamab | GH Research PLC (GHRS) |
Frequently asked questions
How many drugs are in development for CNS Lymphoma?
BioSniper tracks 1 drug in development for CNS Lymphoma across 1 company.
How many clinical trials target CNS Lymphoma?
There are 2 clinical trials targeting CNS Lymphoma tracked by BioSniper.
What is the prevalence of CNS Lymphoma?
The estimated prevalence of CNS Lymphoma is approximately 56.0 per 100,000 population.
Deep-dive into CNS Lymphoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis